Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • Kimberly
    Online Facilitator
      Post count: 4288

      The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA’s review process:

      https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease

      Kimberly
      Online Facilitator
        Post count: 4288
      Viewing 2 posts - 1 through 2 (of 2 total)
      • You must be logged in to reply to this topic.